Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2010 - 2025)
Arbutus Biopharma (ABUS) posted Non-Current Deffered Revenue of $2.9 million for Q1 2025, little changed sequentially from $2.9 million in Q4 2024.
Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2010 - 2025) Analysis & Trends
Arbutus Biopharma has reported Non-Current Deffered Revenue for 12 years, with the latest figure at $2.9 million in Q1 2025.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $2.9 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.9 million (changed N/A YoY) and the FY2024 annual result came in at $2.9 million, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $2.9 million in Q1 2025 per ABUS's latest filing, from $2.9 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $15.6 million in Q1 2022 and troughed at $2.9 million in Q4 2024.
- A 4-year average of $7.4 million and a median of $6.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 78.85% in 2023, down 78.85% in 2023.
- Over 4 years, Non-Current Deffered Revenue stood at $6.0 million in 2022, then slumped by 45.06% to $3.3 million in 2023, then fell by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.9 million, $2.9 million, and $3.3 million for Q1 2025, Q4 2024, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Mar 31, 2023 | 3.30 Mn |
| Dec 31, 2022 | 6.00 Mn |
| Sep 30, 2022 | 10.59 Mn |
| Jun 30, 2022 | 10.84 Mn |
| Mar 31, 2022 | 15.59 Mn |
| Dec 31, 2018 | 645,000.00 |
| Sep 30, 2018 | 656,000.00 |
| Jun 30, 2018 | 689,000.00 |
| Mar 31, 2018 | 693,000.00 |
| Dec 31, 2017 | 693,000.00 |
| Sep 30, 2017 | 744,000.00 |
| Jun 30, 2017 | 4.13 Mn |
| Mar 31, 2017 | 4.78 Mn |
| Dec 31, 2015 | 213,000.00 |
| Sep 30, 2015 | 6.89 Mn |
| Jun 30, 2015 | 8.05 Mn |
| Mar 31, 2015 | 7.90 Mn |
| Dec 31, 2014 | 9.94 Mn |